Neurotechnology for Pain

被引:5
|
作者
Fisher, Lee E. [1 ,2 ,3 ]
Lempka, Scott F. [4 ,5 ]
机构
[1] Univ Pittsburgh, Dept Phys Med & Rehabil, Rehab Neural Engn Labs, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA
[3] Carnegie Mellon Univ, Dept Biomed Engn, Pittsburgh, PA 15213 USA
[4] Univ Michigan, Dept Biomed Engn, Biointerfaces Inst, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA
关键词
chronic pain; deep brain stimulation; pain management; peripheral nervous system; spinal cord stimulation; transcutaneous electric nerve stimulation; SPINAL-CORD STIMULATION; DEEP BRAIN-STIMULATION; MOTOR CORTEX STIMULATION; DORSAL-ROOT GANGLION; CHRONIC NEUROPATHIC PAIN; LOW-BACK-PAIN; KILOHERTZ-FREQUENCY; NERVE-STIMULATION; CONDUCTION BLOCK; INTRACTABLE PAIN;
D O I
10.1146/annurev-bioeng-111022-121637
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Neurotechnologies for treating pain rely on electrical stimulation of the central or peripheral nervous system to disrupt or block pain signaling and have been commercialized to treat a variety of pain conditions. While their adoption is accelerating, neurotechnologies are still frequently viewed as a last resort, after many other treatment options have been explored.We review the pain conditions commonly treated with electrical stimulation, as well as the specific neurotechnologies used for treating those conditions. We identify barriers to adoption, including a limited understanding of mechanisms of action, inconsistent efficacy across patients, and challenges related to selectivity of stimulation and off-target side effects. We describe design improvements that have recently been implemented, as well as some cutting-edge technologies that may address the limitations of existing neurotechnologies. Addressing these challenges will accelerate adoption and change neurotechnologies from last-line to first-line treatments for people living with chronic pain.
引用
收藏
页码:387 / 412
页数:26
相关论文
共 50 条
  • [31] Emulating future neurotechnology using magic
    Olson, Jay A.
    Cyr, Marieve
    Artenie, Despina Z.
    Strandberg, Thomas
    Hall, Lars
    Tompkins, Matthew L.
    Raz, Amir
    Johansson, Petter
    CONSCIOUSNESS AND COGNITION, 2023, 107
  • [32] Commercializing cognitive neurotechnology—the ethical terrain
    Margaret L Eaton
    Judy Illes
    Nature Biotechnology, 2007, 25 : 393 - 397
  • [33] Coping with Brain Disorders using Neurotechnology
    Valdes-Sosa, Pedro A.
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2012, 19 (01): : 1 - 3
  • [34] Clinical neuroscience and neurotechnology: An amazing symbiosis
    Cometa, Andrea
    Falasconi, Antonio
    Biasizzo, Marco
    Carpaneto, Jacopo
    Horn, Andreas
    Mazzoni, Alberto
    Micera, Silvestro
    ISCIENCE, 2022, 25 (10)
  • [35] Neurotechnology and society (2010-2060)
    Lynch, Z
    COEVOLUTION OF HUMAN POTENTIAL AND CONVERGING TECHNOLOGIES, 2004, 1013 : 229 - 233
  • [36] Commercializing cognitive neurotechnology - the ethical terrain
    Eaton, Margaret L.
    Illes, Judy
    NATURE BIOTECHNOLOGY, 2007, 25 (04) : 393 - 397
  • [37] Investments Boost Neurotechnology Career Prospects
    Perkel, Jeffrey M.
    SCIENCE, 2014, 346 (6209) : 653 - 655
  • [38] Advocating for neurodata privacy and neurotechnology regulation
    Yuste, Rafael
    NATURE PROTOCOLS, 2023, 18 (10) : 2869 - 2875
  • [39] Neurotechnology biomarkers in Friedreich's ataxia
    Nageshwaran, S.
    Gavriel, C.
    Sylaidi, A.
    Lourenco, P.
    Athanasopoulos, S.
    Lorenz, R.
    Thomik, A.
    Festenstein, R.
    Faisal, A.
    MOVEMENT DISORDERS, 2015, 30 : S358 - S358
  • [40] Protect freedom of thought in the age of neurotechnology
    Bublitz, Christoph
    NATURE, 2024, 630 (8015) : 35 - 35